38 results about "Sequence motif" patented technology

In various aspects and embodiments, the invention provides a nucleic acid molecule comprising a nucleotide sequence encoding a 7β-hydroxysteroid dehydrogenase (7β-HSDH) mutant that catalyzes at least the stereospecific enzymatic reduction of a 7-ketosteroid to the corresponding 7-hydroxysteroid, wherein the mutant has, compared to the wildtype 7β-HSDH of SEQ ID NO:2, a decreased substrate inhibition and / or an altered cofactor usage, and the mutant has, in comparison with the wildtype 7β-HSDH of SEQ ID NO:2, 1 to 15 amino acid additions, substitutions, deletions and / or inversions in the sequence motif VMVGRRE corresponding to positions 36 to 42 of SEQ ID NO:2.

Screening assays are used to identify mutant homogentisate solanesyl transferase (HST) enzymes which are at least partially resistant to HST-inhibiting herbicides. Nucleic acids encoding the mutant HST enzyme proteins are made available and useful in modifying plants and plant parts so that they can be made herbicide resistant. Crop plants which express the mutant HST enzymes can be grown in the field and herbicides used to controlling unwanted other vegetation. The homogentisate solanesyltransferase (HST) enzyme or an active fragment thereof comprises the amino acid sequence motif: F[V / M]TX[F / Y] (SEQ ID NO: 1), wherein X is any amino acid; and wherein one or more of the amino acid residues of the motif are mutated.

Disclosed is a method for diagnosing cancer and predicting a cancer type using fragment end motif frequencies and sizes of cell-free nucleic acid, and more preferably, to a method for diagnosing cancer and predicting a cancer type by extracting nucleic acids from a biological sample to obtain sequence information, acquiring fragment end motif frequencies and sizes of nucleic acids based on the aligned reads, converting the fragment end motif frequencies and sizes of nucleic acids into vectorized data, inputting the vectorized data to a trained artificial intelligence model and analyzing a resulting calculated value. The method includes generating vectorized data and analyzing the same using an AI algorithm and thus is useful due to high sensitivity and accuracy thereof even in the case of low read coverage.

To provide a fusion polypeptide.SOLUTION: A fusion polypeptide comprising at least one extended recombinant (XTEN) polypeptide fused to the N-terminus or C-terminus of a biologically active polypeptide, wherein the XTEN polypeptide is 150-3,000 amino acids in length, has a plurality of non-overlapping sequence motifs that are each 9-14 amino acids in length, and wherein at least 90% of amino acid residues of the XTEN polypeptide are glycine, alanine, serine, threonine, glutamic acid, or proline, and wherein the XTEN polypeptide comprises a barcode fragment, wherein the barcode fragment is 4-20 amino acids in length, occurs only once within the fusion polypeptide, and is located within a region that is 5%-50% of the length of the XTEN polypeptide as measured from an end of the XTEN polypeptide distal to the biologically active polypeptide.SELECTED DRAWING: Figure 3

The present invention is in the field of genetic editing tools and methods of genetic endineering. It relates to the engineering of rare-cutting endonucleases designed to contract highly repetitive motives in chromosomes, which are at the origin of certain genetic diseases, in particular the so-called "triplet repeat diseases", such as the Huntington disease. The invention encompasses the method for contracting the repetitive motives, the rare-cutting endonucleases for use to contract repetitive motives in a gene subjected to repeat disorder, the polynucleotides and vectors encoding thereof as well as the resulting pharmaceutical compositions.

The present invention relates to methods for engineering the variable region of antibodies or antigen binding fragments thereof, in particular to reduce the effect of anti-drug antibodies. In one aspect, there is provided a monoclonal antibody or antigen-binding fragment thereof, wherein an amino acid sequence of the antibody or fragment thereof is engineered to reduce immunogenicity of the antibody or fragment thereof when the antibody or fragment thereof is administered to a subject, wherein the amino acid sequence is engineered to comprise one or more N-X-S and / or N-X-T sequence motifs in a variable region of the monoclonal antibody or fragment thereof, and wherein X is any amino acid other than proline.

The present invention relates to a nutritionally optimized synthetic or recombinant collagen peptide comprising at least one amino acid sequence motif (glycine-X-Y)n, and the collagen peptide according to the invention for use in a method for therapeutic treatment of the human or animal body and products containing the collagen peptide according to the invention.

This document discloses polypeptides comprising an extended recombinant polypeptide (XTEN) containing multiple overlapping sequence motifs and one or more barcode fragments, which are releasable upon protease digestion and detectable from all other protease-releasable fragments. Some embodiments of these polypeptides also comprise a bioactive polypeptide, wherein advantageous embodiments include a protease-cleavable releasable segment capable of cleaving the link between the XTEN polypeptide and the bioactive polypeptide. Methods for preparing and using the polypeptides are also disclosed.

Described herein are olfactory receptor proteins having a modified C-terminal domain comprising a specific amino acid sequence motif, as well as related nucleic acid molecules, expression vectors, recombinant host cells, libraries, and methods and uses.

The invention relates to the field of gene editing, in particular to engineered cytosine deaminase as well as application and a method of the engineered cytosine deaminase in preparation of a DNA (deoxyribonucleic acid) or RNA (ribonucleic acid) site-specific base editing system, and the engineered cytosine deaminase is a substance obtained by mutation of any one or more of the following sites on a protein with an amino acid sequence as shown in SEQ ID NO.1: H11, H16, K30, T31, H56, Y132 and C171. The engineered cytosine deaminase can be used in a DNA or RNA base editing system, gene editing is more accurate and efficient, the off-target rate is low, and a CBE-ProACD base editing system can efficiently edit cytosine C in a GC motif of a target sequence.

The disclosure features chimeric antigen receptor (CAR) ligands, methods for making the same, and immunomodulatory compositions comprising the CAR ligands. The disclosure also features compositions and methods of using the immunomodulatory compositions, for example, to stimulate activation of CAR expressing cells.

The present invention relates to a synthetic DNA construct comprising (A) a nucleic acid encoding transfer RNA and (B) a 5' leader sequence, wherein the 5' leader sequence contains a sequence motif for controlling the expression level of the transfer RNA.

Described herein are olfactory receptor proteins having modified C-terminal domains containing specific amino acid sequence motifs, as well as related nucleic acid molecules, expression vectors, recombinant host cells, libraries, and methods and uses.

A barcode for use in nucleic acid sequencing includes a combinatorial barcode sequence including at least two iterations of a sequence motif, the sequence motif comprising a first nucleotide base from a first group of nucleotide bases, followed by a second nucleotide base from a second group of nucleotide bases, followed by a third nucleotide base from a third group of nucleotide bases. The first group, the second group, and the third group differ from each other; two groups of the first, second, and third groups contain at least two different nucleotide bases; and at least one of the first, second, and third groups comprises at least three different nucleotide bases; and the combinatorial barcode sequence is one of at least eight potential combinatorial barcode sequences exhibiting the plurality of attributes, and the potential combinatorial barcode sequences are synchronized in flow space based on the predetermined order of nucleotide flows.

The present invention relates to a modified fibroin including a domain sequence represented by Formula 1: [(A)n motif-REP]m or Formula 2: [(A)n motif-REP]m-(A)n motif, and having a serine residue content rate of less than 5.5%.[In Formula 1 and Formula 2, the (A)n motif represents an amino acid sequence consisting of 4 to 27 amino acid residues, and the number of alanine residues with respect to the total number of amino acid residues in the (A)n motif is 80% or more. REP represents an amino acid sequence consisting of 10 to 200 amino acid residues. m represents an integer of 10 to 300. The plurality of (A)n motifs may be the same amino acid sequence or different amino acid sequences. A plurality of REPs may be the same amino acid sequence or different amino acid sequences.]

The present invention relates to methods for engineering the variable region of antibodies or antigen binding fragments thereof that bind TNF alpha to reduce the effect of anti-drug antibodies. In one aspect, there is provided a monoclonal antibody or antigen-binding fragment thereof, wherein an amino acid sequence of the antibody or fragment thereof is engineered to reduce immunogenicity of the antibody or fragment thereof when the antibody or fragment thereof is administered to a subject, wherein the amino acid sequence is engineered to comprise one or more N-X-S and / or N-X-T sequence motifs in a variable region of the monoclonal antibody or fragment thereof, and wherein X is any amino acid other than proline.

Disclosed herein are polypeptides comprising an extended recombinant polypeptide (XTEN) comprised of a plurality of overlapping sequence motifs and one or more barcode fragments releasable upon protease digestion and detectable from ail other proteolytic-ally releasable fragments. Certain embodiments of these polypeptides further comprise a biologically active polypeptide, wherein advantageous embodiments thereof comprise a releasable segment capable of proteolytic cleavage that cleaves the linkage between the XTEN polypeptide and the biologically active polypeptide. Methods of making and methods of using said polypeptides are also disclosed.

A grade of a specific microbial disease in a biological sample of a subject is determined. In one example, masked microbial reference genomes are used to determine the amount of free DNA molecules corresponding to a particular microbial species associated with a particular microbial disease. The masking may remove an area shared with another. In another example technique, end motifs are used for free DNA fragments from a subject and from a particular microbial species. A correlation between a subject and an amount of a set of terminal sequence motifs of a particular microbial species may be determined. The two groups of quantities of positive subjects are substantially more correlated than negative subjects.

The invention discloses a glycosylation point prediction method and device, a medium and equipment. The method comprises the following steps: firstly traversing a to-be-predicted protein sequence, finding out to-be-evaluated point locations conforming to an asparagine-X-serine or threonine sequence motif, then labeling the corresponding asparagine point locations and the serine or threonine point locations, inputting the labeled asparagine point locations and the labeled serine or threonine point locations into a protein language model to obtain a corresponding embedding matrix, and finally, predicting the protein sequence according to the embedding matrix. The method comprises the following steps: performing difference processing on two embedding matrixes and an embedding matrix output by a target protein original sequence, calculating L2 norms according to point locations to obtain two vectors, calculating a normalized cross mean value according to vector element values on the corresponding point locations to obtain an evaluation value, and comparing the evaluation value with a threshold value to judge whether the N glycosylation site is an N glycosylation site or not. Therefore, the N glycosylation site on the to-be-predicted protein sequence is obtained. Compared with the prior art, various test indexes are excellent, especially accuracy and precision are high, and the method adopts the pre-training model and does not need additional machine training.

A method of analyzing a cfDNA from a biological sample to determine a level of a pathology in the biological sample of a subject comprises (i) determining an end sequence motif of at least one end of

The invention provides a circular RNA (Ribonucleic Acid) expression framework as well as application and a method thereof, the expression framework comprises an upstream expression framework and a downstream expression framework, the upstream expression framework comprises a sequence Motif 1 and a complementary sequence thereof, or Motif 2 and a complementary sequence thereof; the downstream expression framework comprises a sequence Motif 3 and a complementary sequence thereof; the Motif 1 is HKDNNWHDHNHNDHNHNHNDHWNWWHDHAB, and the Motif 1 is The Motif 2 is NYBYTMYWTYBYHHVIAG, and the Motif 2 is The Motif 3 is DDKDKHH, and the Motif 3 is Wherein H is A or C or T, K is G or T, D is A or G or T, N is A or C or G or T, W is A or T, B is C or G or T, Y is C or T, M is A or C, and V is A or C or G; the circular RNA established by the circular RNA expression framework provided by the invention is higher in expression efficiency, can be accurately cyclized without generating a'scar sequence ', is low in immunogenicity, can realize the expression of circular RNA with various lengths, can construct a cell strain for stably expressing the target circular RNA, and provides a more advantageous tool for fundamental research and vaccine development of the circular RNA.

The technology relates in part to estimating fetal fraction in non-invasive prenatal testing using one or more fragmentomics parameters. In some aspects, the technology relates to estimating fetal fraction according to nucleic acid fragment lengths and sequence motif frequencies.

Described herein are olfactory receptor proteins having a modified C-terminal domain comprising a specific amino acid sequence motif, as well as related nucleic acid molecules, expression vectors, recombinant host cells, libraries, and methods and uses.

A method of analyzing a cfDNA from a biological sample to determine a level of a pathology in the biological sample of a subject comprises (i) determining an end sequence motif of at least one end of

A method for identifying adjacent sequence motifs, potency and specificity of nuclease is disclosed.

The present disclosure provides a structurally related family of pro-gelling decarboxylase homologues for use in commercial foods and cosmetics. The GPDH protein is expressed in cells in plants, animals and eukaryotic microorganisms in a trace form, and plays a catalytic role in a mevalonic acid pathway. Members of the GPDH family are structurally associated with one another through a series of strictly conserved amino acid sequence motifs. The ability to promote gelation when GPDH is used as a commercial product ingredient has been unclear yet before. The low gelation onset temperature (about 50 DEG C) and very low critical gelation concentration (4%) make the GPDH proteins of the present disclosure particularly suitable as functional protein substitutes in food and personal care products compared to most commonly used plant proteins and plant protein isolates.

The present invention relates to barcoded XTEN polypeptides and compositions thereof and methods of making and using the same, specifically disclosing polypeptides comprising an extended recombinant polypeptide (XTEN) comprising a plurality of overlapping sequence motifs and one or more barcode fragments that are releasable upon protease digestion and detectable from all other proteolytically releasable fragments. Certain embodiments of these polypeptides further comprise a biologically active polypeptide, with advantageous embodiments thereof comprising a proteolytic cleavage releasable segment capable of cleaving the linkage between the XTEN polypeptide and the biologically active polypeptide. Methods of making the polypeptides and methods of using the polypeptides are also disclosed.

Disclosed is a method for diagnosing cancer and predicting a cancer type using fragment end motif frequencies and sizes of cell-free nucleic acid, and more preferably, to a method for diagnosing cancer and predicting a cancer type by extracting nucleic acids from a biological sample to obtain sequence information, acquiring fragment end motif frequencies and sizes of nucleic acids based on the aligned reads, converting the fragment end motif frequencies and sizes of nucleic acids into vectorized data, inputting the vectorized data to a trained artificial intelligence model and analyzing a resulting calculated value. The method includes generating vectorized data and analyzing the same using an AI algorithm and thus is useful due to high sensitivity and accuracy thereof even in the case of low read coverage.

A method for measuring a fractional concentration of DNA from a first tissue type in a biological sample of a subject, the biological sample comprising cell-free DNA, the method comprises analysing a plurality of cell-free DNA molecules from the biological sample of the subject by (a) determining a genomic position in a reference genome corresponding to at least one end of the cell-free DNA molecule, (b) identifying a first set of CpG sites that all have a first differential methylation for the first tissue type in the reference genome, wherein the first set of CpG sites includes one or more CpG sites, (c) determining a first amount of cell-free DNA molecules ending at one of 0 or -1 position of any one of the first set of CpG sites or alternatively, (c) determining an end sequence motif of at least one end of the cell-free DNA molecule, wherein an end of the cell-free DNA molecule has a first position at an outermost position, a second position that is next to the first position, and a third position that is next to the second position; and (d) determining the fractional concentration of DNA from the first tissue type in the biological sample by comparing the first amount to a calibration value, wherein the calibration value is determined from one or more calibration samples having known fractional concentrations of DNA from the first tissue type.

The invention belongs to the technical field of deep learning, and particularly relates to an interpretable DNA sequence motif extraction and visualization method based on deep learning, and a motif extraction method based on combination of baseline input constructed based on a data set AGCT background and DeepLIFT attribution. A target motif length is parameterized into a normalized cut-off frequency, and a length controllable positioning frequency domain noise suppression scheme is realized through adjustable low-pass filtering; a screened motif set is obtained according to a dual screening standard formed by Fisher single-side inspection, BH-FDR correction and an effect quantity threshold value in a combined mode; an integrated link from site-by-site attribution to frequency domain noise suppression and length adjustability to statistics double-threshold robust screening to database comparison verification is established while the capability of capturing long-short motifs with different scales is ensured; the motif extraction not only can reflect the internal discrimination basis of the model, but also can maintain repeatable, comparable and traceable biological reliability in different data fields and application scenes.